Join Growin Stock Community!

Fulcrum therapeutics, inc.FULC.US Overview

US StockHealthcare
(No presentation for FULC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

FULC AI Insights

FULC Overall Performance

FULC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

FULC Recent Performance

-5.97%

Fulcrum therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

FULC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

FULC Key Information

FULC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

FULC Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Price of FULC

FULC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

FULC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.38
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.66
PB Ratio
2.90
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-0.64%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.38
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.66
PB Ratio
2.90
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-0.64%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is FULC's latest earnings report released?

    The most recent financial report for Fulcrum therapeutics, inc. (FULC) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FULC's short-term business performance and financial health. For the latest updates on FULC's earnings releases, visit this page regularly.

  • How much debt does FULC have?

    As of the end of the reporting period, Fulcrum therapeutics, inc. (FULC) had total debt of 6.44M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does FULC have?

    At the end of the period, Fulcrum therapeutics, inc. (FULC) held Total Cash and Cash Equivalents of 198.73M, accounting for 0.54 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is FULC's EPS continuing to grow?

    According to the past four quarterly reports, Fulcrum therapeutics, inc. (FULC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of FULC?

    Fulcrum therapeutics, inc. (FULC)'s Free Cash Flow (FCF) for the period is -16.96M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 0.21% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.